CTLA4 and neoplasm: The patient received radiotherapy in three fractions of 9.5 Gy, a regimen comparable to the regimen (8 Gy × 3) showing optimal synergy with anti-CTLA-4 therapy in mouse tumor models (Dewan et al., 2009).